Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 22, 2021 08:30 ET | Source: Acer Therapeutics Inc.

Relief and Acer Therapeutics Sign Collaboration and License Agreement for Worldwide Development and Commercialization of ACER-001 for the Treatment of Urea Cycle Disorders and Maple Syrup Urine Disease

Relief to potentially pay Acer up to $36 million and royalties in exchange for net profit share and territory rights ACER-001 pre-NDA meeting with U.S. FDA scheduled in Q2 2021 GENEVA and NEWTON,...
March 01, 2021 16:05 ET | Source: Acer Therapeutics Inc.

Acer Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

NEWTON, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...
March 01, 2021 08:30 ET | Source: Acer Therapeutics Inc.

Acer Therapeutics to Participate in March Virtual Investor Conferences

NEWTON, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...
February 11, 2021 08:30 ET | Source: Acer Therapeutics Inc.

Acer Therapeutics Announces Topline Results from its Bioequivalence Trial of ACER-001 Compared to BUPHENYL® Under Fed Conditions

NEWTON, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...
January 25, 2021 08:35 ET | Source: Acer Therapeutics Inc.

Relief Therapeutics and Acer Therapeutics Sign Option Agreement for Exclusivity to Negotiate a Collaboration and License Agreement for the Worldwide Development and Commercialization of ACER-001 for the Treatment of Urea Cycle Disorders and Maple Syrup Urine Disease

Acer to receive $1 million payment to obtain exclusivity and a $4 million loan from Relief Companies working toward negotiation and execution of a definitive collaborationand license agreement by...
December 22, 2020 08:30 ET | Source: Acer Therapeutics Inc.

Acer Therapeutics Announces Full Enrollment of Pivotal Bioequivalence Trial of ACER-001 for Urea Cycle Disorders

NEWTON, Mass., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...
December 17, 2020 08:30 ET | Source: Acer Therapeutics Inc.

Acer Therapeutics Announces Publication of Vascular Ehlers-Danlos Syndrome (vEDS) Patient Registry Data from Sweden

NEWTON, Mass., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...
November 10, 2020 16:05 ET | Source: Acer Therapeutics Inc.

Acer Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update

NEWTON, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...
October 01, 2020 08:30 ET | Source: Acer Therapeutics Inc.

Acer Therapeutics to Present at the Virtual BIO Investor Forum Digital

NEWTON, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...
August 25, 2020 09:00 ET | Source: Acer Therapeutics Inc.

Acer Therapeutics to Virtually Present at Upcoming Investor Conferences

NEWTON, Mass., Aug. 25, 2020 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right